Novo Nordisk (NVO) EBITDA US GAAP (year values) |
|||||||||
2021 | 2021 | 2022 | 2022 | 2023 | LTM ? | CAGR 5 years ? | |||
EBITDA | ? | 65 394 000 000 | 67 556 000 000 | 76 802 000 000 | 82 040 000 000 | 112 940 000 000 | 130 969 000 000 | ||
Changes by years, y/y, % | +9% | +3% | +14% | +7% | +38% | +17.2% |
Novo Nordisk. EBITDA US GAAP
Novo Nordisk. EBITDA US GAAP, changes, %
Novo Nordisk. EBITDA US GAAP, sum by quarters
Novo Nordisk (NVO) EBITDA US GAAP (quarter values) |
||||||||
2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | 2024Q2 | LTM ? | |||
EBITDA | ? | 26 712 000 000 | 32 756 000 000 | 28 511 000 000 | 35 328 000 000 | 34 374 000 000 | 130 969 000 000 | |
Changes by years, y/y, % | +23% | +38% | +176% | +28% | +29% | |||
Changes by quarters, q/q, % | +23% | -13% | +24% | -3% |